Systematic review / meta-analysis / 2012
Calcium supplementation increased gastrointestinal adverse events, which may explain higher rates of self-reported myocardial infarction.
This study reviewed randomized controlled trial (RCT) evidence to clarify adverse events related to calcium supplementation and examine self-reported myocardial infarction (MI). In seven RCTs, self-reported gastrointestinal (GI) adverse event rates were significantly more common with calcium (14.1%) than placebo (10.0%; RR 1.43, 95% CI 1.28-1.59, p < 0.001). Adjudicated functional GI hospitalizations in one study were 6.8% with calcium versus 3.6% with placebo (RR 1.92, 95% CI 1.21-3.05, p = 0.006). In two trials comparing self-reported and adjudicated MI, self-reported MI was 3.6% with calcium and 2.1% with placebo, but after adjudication rates were 2.4% vs. 1.6% (RR 1.45, 95% CI 0.88-2.45, p = 0.145).
- Study type
- Systematic review and meta-analysis of randomized controlled trials
- Who was studied
- Participants across randomized controlled trials of calcium supplementation
- What was measured
- Gastrointestinal adverse events and self-reported vs. adjudicated myocardial infarction
THE PAPER
Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation.
Lewis JR, Zhu K, Prince RL. J Bone Miner Res, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.